MBTD1

MBTD1 is a Polycomb-group nuclear protein that functions as a methyl-lysine histone reader and serves as a recruitment module for the NuA4/TIP60 histone acetyltransferase complex, governing DNA repair pathway choice and hematopoietic stem cell quiescence (PMID:19841675, PMID:32209463, PMID:37523546). Its four MBT repeats form an asymmetric rhomboid architecture in which a semi-aromatic cage in one repeat preferentially engages mono- and di-methylated lysine histone peptides via a cavity-insertion recognition mode (PMID:19841675). A hydrophobic C-terminal fragment of EPC1 binds the MBT repeats at a site distinct from the methyl-lysine pocket, structurally explaining how MBTD1 is incorporated into the NuA4/TIP60 complex (PMID:32209463); within this complex MBTD1 reads H4K20me to direct TIP60-mediated H2AK15 acetylation, which blocks 53BP1 chromatin loading and thereby influences DNA double-strand break repair (PMID:32209463). In hematopoietic stem cells MBTD1 binds the FoxO3a promoter and associates with TIP60 complex components, acting upstream of FOXO3a to enforce quiescence, since its loss expands stem/progenitor pools and hyperactivates the cell cycle while FOXO3a restoration rescues the defect (PMID:37523546). The oncogenic ZMYND11-MBTD1 fusion mislocalizes the NuA4/TIP60 complex—via MBTD1-mediated TIP60 binding and the ZMYND11 H3K36me3-reading PWWP domain—to the bodies and regulatory elements of pro-leukemic genes including MYC and HOXA clusters, sustaining aberrant histone acetylation and transcriptional activation that drives acute myeloid leukemia (PMID:33594072, PMID:35705031).

1. 2009 High

   Established the structural and biochemical basis for MBTD1 as a methyl-lysine reader, defining how it recognizes histone marks.

   Evidence X-ray crystallography of the four MBT repeats with fluorescence polarization binding and mutagenesis

   PMID:19841675

   Open questions at the time

   • Did not identify the in vivo histone substrate or genomic targets
   • No functional role demonstrated at this stage
2. 2013 Medium

   Linked MBTD1 to maintenance of the H4K20me1 mark by placing it upstream of the methyltransferase Pr-Set7/SET8 during meiotic maturation.

   Evidence Co-IP, siRNA knockdown, and phenocopy analysis in mouse oocytes

   PMID:23475131

   Open questions at the time

   • Mechanism by which MBTD1 stabilizes Pr-Set7 unresolved
   • Single-lab study in a specialized cell type
   • Direct enzymatic relationship not reconstituted
3. 2020 High

   Defined the molecular interface that recruits MBTD1 into the NuA4/TIP60 complex and connected this to DNA repair pathway choice via H2AK15 acetylation and 53BP1 exclusion.

   Evidence Crystal structure of the MBTD1–EPC1 complex with cellular validation and break-repair assays

   PMID:32209463

   Open questions at the time

   • 53BP1 exclusion model described concisely and rests on cellular assays in one paper
   • Quantitative contribution of MBTD1 to repair outcomes not fully mapped
4. 2021 High

   Demonstrated that the ZMYND11-MBTD1 fusion is oncogenic, requiring both TIP60 interaction through MBTD1 and the ZMYND11 PWWP domain to redirect the complex to pro-leukemic genes.

   Evidence ChIP-seq, ATAC-seq, systematic domain mutagenesis, and ex vivo/in vivo murine AML models

   PMID:33594072

   Open questions at the time

   • Single-lab study despite comprehensive methods
   • Therapeutic targetability of the fusion not established
5. 2022 High

   Confirmed biochemical incorporation of the fusion into the endogenous NuA4/TIP60 complex and showed it mislocalizes the complex to gene bodies, altering transcription and splicing to favor Myc-driven self-renewal.

   Evidence Co-purification/MS, ChIP-seq, RNA-seq, and ES cell and hematopoietic self-renewal assays

   PMID:35705031

   Open questions at the time

   • Mechanistic link between mislocalization and alternative splicing not detailed
   • Relative roles of MYC versus other targets in leukemogenesis unresolved
6. 2022 Medium

   Identified upstream transcriptional regulation of MBTD1, with NFYB activating its promoter and lncRNA H19 enhancing this to promote chemoresistance.

   Evidence Luciferase reporter, ChIP-qPCR, siRNA knockdown, and lymphoma models

   PMID:36434485

   Open questions at the time

   • Single-lab study focused on expression regulation rather than MBTD1 mechanism
   • Whether chemoresistance depends on MBTD1 reader/complex functions untested
7. 2023 High

   Established a physiological role for MBTD1 in HSC quiescence by placing it upstream of FOXO3a through direct promoter binding and TIP60 complex association.

   Evidence Conditional knockout mice, ChIP at the FoxO3a promoter, Co-IP, and genetic rescue with FOXO3a restoration

   PMID:37523546

   Open questions at the time

   • How MBTD1 activates FoxO3a transcription mechanistically not defined
   • Connection between HSC quiescence role and the DNA-repair reader function not integrated

• How MBTD1's methyl-lysine reading, repair-pathway control, and transcriptional/HSC functions are mechanistically unified, and whether the ZMYND11-MBTD1 fusion is therapeutically targetable, remain open.
• No integrated model linking H4K20me reading to FoxO3a regulation
• No structural data on MBTD1 within the assembled NuA4/TIP60 complex
• Druggability of the fusion or MBTD1–EPC1 interface untested